Blog

Inovio And Collaborators Receive NIH Grant To Evaluate HIV Immunotherapy PENNVAX®-GP’s Ability To Induce … – Clinical Leader


Philly.com

Inovio And Collaborators Receive NIH Grant To Evaluate HIV Immunotherapy PENNVAX®-GP's Ability To Induce …
Clinical Leader
This is a two-step clinical study in HIV-positive subjects to assess Inovio's HIV immunotherapy PENNVAX-GP with INO-9012 (an IL-12 immune activator) alone and with the addition of a PD-1 checkpoint inhibitor. All trials will be randomized, double-blind
Inovio Pharmaceutical's DNA vaccine will be tested in patients with HIVPhilly.com


Immune Check Activators Market — Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024Medgadget (blog)

all 3 news articles »

2017-03-31 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.